Login to Your Account


TWO FOR THREE IN ITP

As investors look ahead to results later this year from the second phase III trial with Rigel Pharmaceuticals Inc.'s fostamatinib, principal investigator James Bussel said "the fact that, at least so far, the results in this [first] phase III trial mimic and are very similar to the first phase II trial gives all of us on the Rigel team a lot of confidence."

more »


Analysis

Although Infinity Pharmaceuticals Inc. CEO Adelene Perkins said her firm's "going-in assumption is that we will be successful" in selling rights to phosphoinositide 3-kinase (PI3K) inhibitor duvelisib, Abbvie Inc.'s decision to pull out of their partnership undoubtedly threw cold water on the class.

read more »